HOME >> BIOLOGY >> NEWS
A cytokine not kind to an injury of the spine

Transverse Myelitis (TM) is an autoimmune inflammatory disease of the central nervous system that is characterized by focal spinal cord demyelination and axonal injury. TM causes paralysis and other neurologic disabilities, but has limited treatment options due to a lack of understanding of its underlying mechanisms.

In a paper appearing online on September 22 in advance of print publication of the October 1 issue of the Journal of Clinical Investigation, Douglas Kerr and colleagues from Johns Hopkins find that levels of the cytokine IL-6 are selectively increased in cerebrospinal fluid from TM patients. The researchers show that elevated IL-6 levels alone are necessary and sufficient to mediate injury to both neuronal and glial cells, in a manner that is dependent on nitric oxide.

This is the first description of IL-6 as a mediator of neural injury. Further, high levels of IL-6 were directly correlated with tissue injury and clinical disability, suggesting that IL-6 may be an important biomarker of TM. This new data may aid in the development of effective therapies against TM and other inflammatory diseases of the central nervous system.


'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
22-Sep-2005


Page: 1

Related biology news :

1. The cytokine diet: The next fad in weight loss?
2. University of Cincinnati receives $1.7M to research molecular treatment of brain injury
3. Stem cells decrease ischemic injury and restore brain function
4. Deflecting damage: Flexible electronics aid brain injury research
5. Estrogen protects liver after traumatic injury
6. Uric acid and spinal cord injury treatment
7. Cell death following blood reflow injury tracked to natural toxin
8. Key to acute lung injury lies in Ang2 protein
9. In young rats, researchers find a reaction to spinal cord injury that speeds recovery
10. How brain injury leads to seizures, memory problems
11. Spinal cord bridge bypasses injury to restore mobility

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... ... MultiMountTM weigh modules. These weigh modules are designed according to European Hygienic ... (NSF). , As fully integrated weighing solutions, SWB805 MultiMount weigh modules reduce ...
(Date:3/27/2017)... WARREN, N.J. , March 27, 2017 Roka ... providing advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Spring 2017 Convention on March ... the New York Marriott Marquis. About Roka ... ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture ... added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... USA ) and the US National Institutes of Health. ... ... Logo ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is ... (CTC) conference presented by The Conference Forum in Boston on April 3-4, 2017. The ... drive improved clinical trial outcomes and bring them closer to the patient. Clinical Trial ...
Breaking Biology Technology:
Cached News: